Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin.
about
CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapyAntibody Drug Conjugates: Preclinical ConsiderationsSynthesis of a dual functional anti-MDR tumor agent PH II-7 with elucidations of anti-tumor effects and mechanismsZosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML).P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patientsPhase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumorsGemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.Tumour-targeted chemotherapy with immunoconjugates of calicheamicin.Strategies for overcoming p-glycoprotein-mediated drug resistance in acute myeloblastic leukaemia.CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.The role of gemtuzumab ozogamicin in acute leukaemia therapy.Molecular mechanisms of drug resistance in acute myeloid leukaemia.Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicinA phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia.Novel targeted drug therapies for the treatment of childhood acute leukemiaCellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.Antibody-based therapy of leukaemia.Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy.Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia.Recent advances in acute myeloid leukemia stem cell biologyPharmacogenomic considerations of xenograft mouse models of acute leukemia.Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.Gemtuzumab ozogamicin in acute myeloid leukemia revisited.Novel approaches to pediatric leukemia treatment.Gemtuzumab ozogamicin in acute myeloid leukemia.Antibody-drug conjugates: recent advances in conjugation and linker chemistries.Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells.Antigen-directed therapies: an effective tool in acute myeloid leukemia?The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia.NFATc1 as a therapeutic target in FLT3-ITD-positive AML.Curcumin Enhanced Busulfan-Induced Apoptosis through Downregulating the Expression of Survivin in Leukemia Stem-Like KG1a CellsHematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia.Effect of monensin liposomes on the cytotoxicity of anti-My9-bR immunotoxin.Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia.Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo.Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial.High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients.Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications.Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia.
P2860
Q24678297-9D080523-331B-4671-9D94-A966BADC6D26Q27022321-DD6C7B75-E6D7-45D4-93E9-A9608DC156B3Q28481389-65A883BD-5DA7-4CFE-9396-AC58C6F5037FQ33319637-33F834C2-4E6A-4A14-99E3-921E366B5D03Q33472987-29905B75-94A3-4E94-AD9D-694CF37938A7Q33729158-E736C542-2C30-4203-87F0-F8BD23979884Q34218976-968E6DC1-5BED-42B1-8917-16541C751E6BQ35034815-A5D8B9E5-C69B-4ED4-9E04-8DF94760BF31Q35873771-5D3B8C9B-C533-4B8D-984F-571E63220D63Q35918060-A9FF896B-0DEB-40E6-AE2D-72693B298728Q35980938-E72937E7-673A-4F0B-B3CE-B1B886B06B2AQ36367816-01A5ADC7-E17B-4CA5-9DD9-1E3DF6F894D8Q36835812-BC67EAB8-4C65-4F9D-A3C0-7385E32000EAQ36932014-6155812D-72ED-431B-902D-F5F061932750Q37311249-106134C8-ABB0-44A9-A57E-719E9DBA0049Q37477482-9121E6D9-F776-49F1-BE07-2D9C09ACE512Q37512086-F176EB70-6EBB-430E-975A-B43D6B9A5319Q37605247-20C24246-30F6-4D96-B79A-BD0AE7BC282FQ37818248-03C33FEC-D1F2-476C-B864-54DFF5AFBAF9Q37910260-44F750E0-7201-435D-A343-2CC4E85519E2Q38003359-084CD4EF-6526-4A38-A280-27F73811E9C3Q38061500-48C7CFC9-79DF-48A2-94F3-11283E701644Q38109541-3306341B-C633-4F2A-9405-193520369584Q38215269-876E8F66-73CD-4F68-8FF5-13582B73DCE2Q38500371-1A3CD782-F0F4-45F4-8B92-D0C825AEAC80Q38728718-87886D72-D863-4EDA-83C8-B069A4AD621FQ38981429-628EB949-1A7C-4AB5-88FD-8F7FAEE1A675Q39506455-C019A818-42F1-4C05-A501-D962E4D27C04Q40590788-A569FA7D-DBC0-4C24-AC35-98D1EBD73150Q40872029-E05EDA84-E7FE-4030-93B1-5C01200D0FD6Q40937224-E87A920C-A670-4434-930E-F3F29C663DE4Q41861089-8F57C08C-8B37-41B8-B932-933F4D1A16BEQ41925220-33CF3C39-DAB6-44FD-A364-F0862A7CD0E1Q42166599-F2D607E3-422A-46AD-B8E5-6743C6B2649DQ42699939-EEA0E761-8F3D-442B-99CF-7E1F4D1411AFQ45236184-4436E45A-AB49-4C78-BCD7-700C7BF14E0AQ46236663-63383837-15BC-4CA8-B9BD-9D9A3BAC2033Q47929658-DA147BC3-30B8-468F-99A5-85F0F20C9227Q52593621-5B4C02C6-63BE-4B0E-9C4E-2D1EB46B54EAQ52981533-5BF89711-26C3-4D11-BE0A-68D501384887
P2860
Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin.
@en
Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin.
@nl
type
label
Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin.
@en
Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin.
@nl
prefLabel
Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin.
@en
Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin.
@nl
P2093
P356
P1433
P1476
Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin.
@en
P2093
E L Sievers
I D Bernstein
J M Bennett
L H Leopold
M L Linenberger
M S Berger
T A Gooley
P304
P356
10.1182/BLOOD.V98.4.988
P407
P577
2001-08-01T00:00:00Z